PTC Therapeutics | PTCT - Current Liabilities

Stock Price
69.69
Daily Change
-0.97 -1.37%
Monthly
-8.58%
Yearly
39.32%
Q1 Forecast
68.47

PTC Therapeutics reported $968.43M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
BioCryst Pharmaceuticals USD 190.24M 13.08M Sep/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Ironwood Pharmaceuticals USD 242.5M 9.98M Sep/2025
Karyopharm Therapeutics USD 87.16M 12.06M Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
TG Therapeutics USD 156.81M 15.08M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025
Xencor USD 86.48M 9.6M Sep/2025